Formulation and evaluation of bioadhesive drug delivery system

Asif Pathan, Asish Dev


Objective: The objective of the work is to formulate gliclazide bioadhesive tablets that will significantly improve the availability of the drug especially under the situations of prolonged use of drug and also reduce the total dosage of administered drug and consequently reduce the side effects. All these factors will ultimately lead to enhanced patient compliance and patient care.

Methods: Various natural and semi synthetic polymers were screened and they were selected on the basis of their swelling and gelling properties. The formulated batches were subjected to various evaluation parameters and optimization was done.

Results: The F7 batch was concluded to be the best batch in which Xanthan gum (70%) and HPMC K4M (30%) were taken. Stability studies of the optimized batches were conducted as per the ICH guidelines.

Conclusions: From this study it was concluded that as the thickness of tablet increases the hardness of tablet decreases which leads to increase in the swelling of the tablet and hence the increase in the drug release.


Gliclazide, Antidiabetic drug, Bioadhesive tablets, Swelling index

Full Text:



Robinson JR, Lee VH. Controlled drug delivery: fundamentals and applications, 2nd ed.; Marcel Dekker Inc; Taylor and Francis: New York; 1987: 3 - 49.

Mubashshir MM, Dev A. Indian Journal of Pharmaceutical and Biological Research. 2015;3(1):18-23.

Mathiowitz E, Chickering DE, Lehr CM. Defination Mechanism and Theories of bioadhesion Bioadhesive Drug Delivery Systems, Marcel Dekker, Eastern Hemisphere Dustribution: USA; 2010: 1-22.

Jain NK. Progress in Controlled and Novel Drug Delivery Systems. CBS. Publisher. Indian binding house press: Noida; 2010: 79–80.

Jain NK. Controlled and Novel Drug Delivery Systems. CBS Publisher: Delhi; 1997: 356.

Saraswathi B, Balaji A, Umashankar MS. Polymers in mucoadhesive drug delivery system-latest updates. Int J Pharm Sci. 2013;423–30.

Singh S, Govind M, Bothara SB. A Review on in vitro - in vivo Mucoadhesive Strength Assessment. Pharma Tech Medica. 2013;221-7.

Tangri P, Madhav NVS. Oral mucoadhesive drug delivery systems: A Review. Int J Biopharm. 2011;2:36–46.

Khurana S, Madhav NVS, Pranshu T. Mucoadhesive drug delivery: Mechanism and method of evaluation: A Review. Int J Pharm Biosci. 2011;2:458–64.

Hiremath SR, Murthy SN. Controlled Drug Delivery Systems, Text book of Industrial Pharmacy, Orient Longman private, India; 2008: 5–17.

Phanindra B, Moorthy BK, Muthukumaran M. Recent advances in mucoadhesive /bioadhesive drug delivery system: A review. Int J Pharm Med Bio Sci. 2013;2:68–73.

Yadav VK, Gupta AB, Kumar R, Yadav JS, Kumar B. Mucoadhesive Polymers: Means of Improving the Mucoadhesive properties of drug delivery system. J Chem Pharm Res. 2010;5:418–32.

Cavalho FC, Bruschi ML, Evangelista RC. Mucoadhesive drug delivery systems: A Review. Int J Pharm Sci. 2010;46:1–17.

Martin A, Swarbrick J, Cammarata A. Physical Pharmacy, 6th ed, Varghese Publishing house: Bombay; 1991: 592–506.

Lee JW, Park JH, Robinson JR. Bioadhesive based dosage forms: The next generation. J Pharm Sci. 2000;89:850–66.

Park JH, Robinson JR. Bioadhesive polymers as platforms for oral controlled drug delivery methods to study bioadhesion. Int J Pharm. 1984;19:107.

Sachan NK, Bhattacharya A. Basics and Therapeutic potentials of oral mucoadhesive microparticulate drug delivery systems. Int J Pharm Cl Res. 2009;10–4.

Diabetes mellitus. wiki/Diabetes_mellitus. Accessed 14 December 2014.

Dandiya PC, Kulkarni SK. Introduction to pharmacology, 6th ed, Vallabh Prakashan, Chandigarh; 2002: 352 – 353.

Bjelakovi G, Nagorni A, Stamenkovi I, Benedeto-Stojanov D, Bjelakovi M, Petrovi B, et al. Diabetes mellitus and digestive disorders: Review article. Acta Fac Med. 2005;1:43–50.

Gliclazide: Gliclazide. Accessed 03 October 2014.

Jhon HB, Jhon MB. Wilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry. Quebecor World Press: Philadelphia; 2004: 670.

Sarkar A, Tiwari A, Bhasin PS, Mitra M. Pharmacological and pharmaceutical profile of gliclazide: A Review. J App Pharm Sci. 2011;1:11–9.

British Pharmacopoeia, 2009, Volume 1, p 937.

Raymond C, Paul JS, Marian EQ. A Handbook of Pharmaceutical Excipients, 4th ed. Pharmaceutical press, Lambeth High Street, London; 5; pp 297 – 299, pp 354 – 356, pp 641 – 643, pp 691 – 692.

HPMC: mellose. Acessed 7 May 2015.

Xanthan gum: Xanthan_gum. Accessed 7 May 2015.

Magnesium stearate: https://en.wikipedia. org/wiki/Magnesium_stearate. Accessed 7 May 2015.

Talc: Accessed 7 May 2015.

Lachman L, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. Varghese Publishing house: Bombay; 2009: 171 – 195

Aulton ME. The Design and Manufacture of Medicines, Livingston Publisher: Elsevier Science 3rd ed.; 2007: 355 – 357.

Aulton ME. Pharmaceutics: The science of dosage form design. Livingston Publisher: Elsevier Science; 2002: 114–115, 289–315, 661.

Adeyeye MC, Brittain HG. Preformulation in solid dosage form development, Informa health care: USA; 2008;178:1–15.

Beckett AH, Stenlake JB. Practical Pharmaceutical Chemistry, CBS publishers, part two, 4th ed.; 275 – 281.

Jamadar SA, Mulye SP, Karekar PS, Pore YV, Burade KB. Development and validation of UV spectrophotometric method for the determination of gliclazide in tablet dosage form. Der Pharma Chemica. 2011;3:338–43.

Dhabale PN, Seervi CR. Simultaneous UV spectrophotometric method for estimation of gliclazide and Metformin hydrochloride in tablet dosage form. Int J Chemtech Res. 2010;2:813–7.

Revathi R, Saravanan VS, Raj MP. Ethiraj T. Ganesan V., Spectrometric estimation of gliclazide in bulk and pharmaceutical dosage forms. Int Res J Pharm. 2010;1:277–81.

Pavia DL, Lampman GM, Kriz GS. Introduction to Spectroscopy; Malloy Lithographing press: USA; p. 13.

Chatwal RG, Shyam KA. Instruments Methods of chemical analysis, Himalaya publishing house: Mumbai; 2008: 2.55.

Shaikh DM, Shende MA, Shaikh AM. Formulation development and evaluation of Gastro Retentive Mucoadhesive Tablets using synthetic polymers. Int J Res Pharm Sci Bio Sci. 2013: 1265.

The Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Govt. of India, Ghaziabad, Indian Pharmacopoeia, 2010, Volume 1: 192–193.

Badgujar P, Shaikh T. Development of dissolution media for marketed gliclazide modified release tablets. Int J Pharm Sci. 2013;4:352–62.

United States Pharmacopoeia 32 and National formulary 27, volume 1, 2009, p. 264-269.

British Pharmacopoeia, 2009, Volume 4 Appendix XII B A 295 – 299.

Lakka NS, Goswami N. Solubility and dissolution profile studies of gliclazide in pharmaceutical formulations by RP – HPLC. Int Res J Pharm. 2012;3:126–9.

Demirturk E, Oner L. Solubility and dissolution properties of gliclazide. J Pharm Sci. 2004;29:21-5.

Nguyen C, Christensen JM, Nguyen T. Application of D-Optimal Study Design with Contour Surface Response for Designing Sustained Release Gliclazide Matrix Tablets. Pharmacology & Pharmacy. 2014;5:620–35.

U.S. Department of Health and Human Services FDA, Guidance for Industry Q1A(R2) Stability Testing Of New Drug Substances and Products, November 2003 ICH Revision 2 pp 5.

Cartensen J. ICH Guidelines. In: Drug Stability Principles and Practices, 2nd ed., New York, Marcel Dekker Inc.; 1995: 541–546.


  • There are currently no refbacks.

Copyright (c) 2016 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations